Genetic testing has become an essential component in the evaluation of atypical parkinsonian disorders, including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD), and related conditions. This guide provides clinicians with evidence-based recommendations for genetic testing in these disorders, covering gene-specific indications, testing methodologies, variant interpretation, and genetic counseling considerations.
Genetic testing in atypical parkinsonism serves multiple clinical purposes:
- Confirmatory diagnosis: Genetic findings can support or refute specific diagnostic hypotheses, particularly when clinical features are ambiguous
- Differential diagnosis: Certain genetic signatures help distinguish between PSP, MSA, CBD, and Parkinson's disease
- Prognostic information: Specific mutations may be associated with disease progression rates and symptom profiles
- Family risk assessment: Identifies at-risk family members who may benefit from predictive testing and counseling
- Therapeutic stratification: Increasingly important as gene-targeted therapies enter clinical trials
PSP has the strongest genetic architecture of any atypical parkinsonian disorder. The primary genetic targets include:
| Gene |
Variant Type |
Clinical Significance |
| MAPT |
H1 haplotype, P301L, P301S, R406W |
Major risk factor; P301L causes familial PSP |
| STX6 |
rs12445022 |
Modest risk increase |
| EIF2AK3 |
Various |
Rare causes |
The MAPT H1 haplotype is present in approximately 95% of PSP patients and increases risk by 3-5 fold compared to the protective H2 haplotype.
MSA is associated with both alpha-synuclein pathology and distinct genetic risk factors:
| Gene |
Variant Type |
Clinical Significance |
| GBA |
N370S, L444P, Recombinant |
5-10x increased risk; earlier onset |
| SNCA |
Multiplications, H1 haplotype |
Increased risk |
| COQ2 |
V343A |
Risk factor, especially in Japanese |
| LRRK2 |
G2019S |
Possible risk modifier |
GBA mutations are particularly important to test for, as they represent the strongest known genetic risk factor for MSA.
CBD shares genetic overlap with PSP, particularly in tau-based pathology:
| Gene |
Variant Type |
Clinical Significance |
| MAPT |
H1 haplotype, P301L |
Major risk factor |
| PSEN1 |
Various |
Rare causes |
| PSEN2 |
Various |
Rare causes |
| GRN |
Null mutations |
TDP-43 pathology association |
When clinical features suggest underlying genetic forms of parkinsonism:
| Gene |
Variant Type |
Associated Phenotype |
| LRRK2 |
G2019S |
Typical PD, but can have PSP-like features |
| GBA |
Various |
PD with earlier onset, may convert to MSA |
| PRKN |
Biallelic null |
Early-onset PD, dystonia |
| PINK1 |
Biallelic |
Early-onset PD |
| VPS35 |
D620N |
Late-onset PD |
| C9orf72 |
Repeat expansions |
PD-FTD spectrum |
Movement disorder gene panels typically include 20-150 genes relevant to parkinsonism and atypical presentations. This approach offers several advantages:
Advantages:
- Cost-effective (typically $500-1500)
- Rapid turnaround (2-4 weeks)
- Focused interpretation
- Adequate for most clinical scenarios
- Includes copy number variation detection for larger genes
Limitations:
- May miss novel genes
- Limited to pre-specified gene sets
- Non-coding variants often not covered
WES sequences all protein-coding regions (~20,000 genes). This approach is appropriate when:
- Targeted panels are negative but clinical suspicion remains high
- Phenotype suggests a novel or rare genetic etiology
- Patient has unusual features suggesting atypical genotype
- Family history suggests autosomal recessive inheritance
Advantages:
- Broader coverage of known genes
- Ability to re-analyze data as new genes are discovered
- Identifies novel disease genes
Limitations:
- Higher cost ($1000-3000)
- Longer analysis time
- Incidental findings possible
- Poor coverage of some regions
- Non-coding variants not covered
WGS provides comprehensive analysis including non-coding regions, structural variants, and repeat expansions:
Advantages:
- Complete genetic coverage
- Best for detecting structural variants
- Repeat expansion detection (with specialized analysis)
- Discovery of novel variants
Limitations:
- Highest cost ($2000-5000)
- Complex interpretation
- Variant of uncertain significance more common
- Requires specialized bioinformatics
flowchart TD
A["Clinical suspicion<br/>Atypical Parkinsonism"] --> B{"Family History?"}
B -->|"Positive"| C["Consider targeted panel<br/>or WES/WGS"]
B -->|"Negative"| D["Start with<br/>targeted panel"]
D --> E{"Panel Results"}
E -->|"Pathogenic variant"| F["Confirm diagnosis<br/>Family testing"]
E -->|"VUS"| G["Consider WES for<br/>expanded analysis"]
E -->|"Negative"| H["Clinical follow-up<br/>Reconsider diagnosis"]
C --> I{"Results"}
I -->|"Diagnostic"| F
I -->|"Inconclusive"| G
G --> J["Functional studies<br/>if available"]
J --> K["Research enrollment<br/>if appropriate"]
Variants are classified according to ACMG guidelines:
| Classification |
Criteria |
Clinical Action |
| Pathogenic |
Strong evidence, meets multiple criteria |
Diagnostic confirmation |
| Likely Pathogenic |
Moderate evidence |
Likely diagnostic, confirm with repeat testing |
| Variant of Uncertain Significance (VUS) |
Insufficient evidence |
Research analysis, family segregation studies |
| Likely Benign |
Moderate evidence against pathogenicity |
Typically not reported |
| Benign |
Strong evidence against |
Not reported |
GBA Variants:
- N370S is the most common pathogenic variant in Gaucher disease
- Complex alleles (recombinant alleles) require careful interpretation
- Heterozygous carriers have increased risk for PD and MSA
- Enzyme activity testing can support functional significance
MAPT H1 Haplotype:
- Determined by specific SNPs in linkage disequilibrium
- H2 haplotype is protective
- Requires haplotype analysis, not single variant testing
- Associated with PSP, CBD, and some FTD cases
C9orf72 Repeat Expansions:
- Pathogenic threshold: >30 repeats (some labs use >40)
- Intermediate alleles (20-30 repeats) have uncertain significance
- Testing requires repeat-primed PCR or Southern blot
- Large normal alleles can exceed 20 repeats in some populations
PRKN/PINK1 Biallelic Variants:
- Autosomal recessive inheritance requires two pathogenic alleles
- Heterozygotes may have slightly increased PD risk
- Large genomic rearrangements possible (deletions/duplications)
- Multiple testing methods often needed
Before genetic testing, patients should understand:
- Possible outcomes: Positive, negative, inconclusive, and incidental findings
- Implications for family members: Autosomal dominant vs. recessive inheritance patterns
- Insurance considerations: GINA protections in the US, but gaps remain
- Psychological impact: Results may affect anxiety, family relationships, life planning
- Limitations of testing: Not all pathogenic variants are detectable
- Variant uncertainty: VUS may not have clear clinical implications
After results are available, counseling should address:
- Pathogenic result: Explanation of specific variant, inheritance pattern, family implications
- VUS: Importance of family studies to reclassify, limitations of current knowledge
- Negative result: Possibility of undetected variants, continued clinical follow-up
- Incidental findings: Secondary variants unrelated to the indication
When a pathogenic variant is identified:
-
Autosomal dominant (LRRK2, GBA, MAPT, C9orf72):
- First-degree relatives have 50% chance of carrying the variant
- Predictive testing available for at-risk adults
- Consider neurological evaluation for prodromal signs
-
Autosomal recessive (PRKN, PINK1, GBA homozygotes):
- Siblings have 25% chance of being affected, 50% chance of being carriers
- Carrier testing for reproductive partners
- Early-onset symptoms warrant evaluation
Young-onset parkinsonism has higher genetic yield:
- Consider PRKN, PINK1, PARK7 testing first
- GBA testing recommended regardless of family history
- WES often appropriate given phenotypic heterogeneity
Rapidly progressive atypical parkinsonism may warrant:
- Priority MAPT testing for PSP suspicion
- Consider COQ2 for MSA with cerebellar features
- Look for compound heterozygous GBA variants
Cognitive impairment in atypical parkinsonism suggests:
- C9orf72 testing for FTD/ALS overlap
- GRN testing for CBD with prominent aphasia
- MAPT for PSP with early frontal symptoms
¶ Cost and Access Considerations
- Many insurers cover genetic testing with appropriate clinical documentation
- Prior authorization often required
- Medicare covers GBA testing in certain contexts
- Self-pay options available ($200-3000 depending on scope)
Consider:
- Clinical certification (CAP, CLIA)
- Variant database membership (ClinGen)
- Turnaround time
- Reporting format and variant classification practices
- Genetic counselor availability